Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.41 |
| ▸ | NEK7 | Q8TDX7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257149 | 0.97 | KIT (0.61) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1256119 | 0.90 | KIT (0.63) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1255022 | 0.89 | KIT (0.64) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1256991 | 0.87 | KIT (0.63) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1256803 | 0.87 | KIT (0.49) | KIT | |
| SCHEMBL1255264 | 0.87 | KIT (0.62) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1256365 | 0.87 | KIT (0.62) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1255143 | 0.84 | KIT (0.59) | KITFLT3CACNA1HNEK7 | |
| SCHEMBL1257345 | 0.83 | KIT (0.47) | KITCACNA1H | |
| SCHEMBL16536315 | 0.82 | KIT (0.62) | KITFLT3CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | claimed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | claimed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | claimed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | KIT 4/4885FLT3 1/4885CACNA1H 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.